Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (9)

2024

  1. Expert-based collaborative analysis of the situation and prospects of biomarker test implementation in oncology in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 985-990

  2. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

2022

  1. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 10, pp. 1274-1286

2018

  1. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

    Oncologist, Vol. 23, Núm. 9, pp. 1092-1102

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

2012

  1. Recommendations for the optimal management of early and advanced urothelial carcinoma

    Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441

  2. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2010

  1. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1

  2. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

    Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1